Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: kinnate.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $35.00 → $11.00 | Buy → Hold | Stifel |
| 7/28/2022 | $33.00 | Buy | H.C. Wainwright |
| 9/27/2021 | $46.00 | Buy | Jefferies |
| 9/23/2021 | $32.00 | Buy | Stifel |
| 7/13/2021 | Outperform | William Blair |
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (("Kinnate", NASDAQ:KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share (together with the base price, the Cash Amount), plus one non-tradeable contingent value right ("CVR") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds from any
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ:KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with the Base Price, the Cash Amount) at the closing of the merger plus a non-transferable contingent value right (CVR), representing the right to receive 85% of the net proceeds from any out license or sale of the Kinnate programs effected within one year of closing of the merger or 100% of the net proceeds from any out license or sale executed prior to the closing. "This
SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13G/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13G/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13G/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13G - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 13G/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023. Ms. DeSimone brings more than forty years of global business expertise in life sciences to Kinnate's board of directors. Dean J. Mitchell, chairman of the Kinnate board of directors, commented, "I am honored to welcome Jill to the Kinnate board of directors. She is an ideal fit given her breadth of experience as a global business leader for multi-billion-dollar oncology medicines, strategic leade
Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors Strengthened management team and Board of Directors with key appointments Ended the quarter with cash, cash equivalents and investments of $365.1 million, exclusive of $35.0 million in its China joint venture SAN FRANCISCO and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021. The company also announc
SAN FRANCISCO and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the appointment of Helen Sabzevari, Ph.D. to its Board of Directors. Dr. Sabzevari is a global thought leader who is internationally recognized for her work in the field of oncology. Her career-long efforts have helped bridge the gap between cancer cell biology and immunology, bringing these disciplines together to understand how the immune system and cancer cells interact on the broader system level and for
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team SAN FRANCISCO and SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the appointment of Neha Krishnamohan as Chief Financial Officer and Executive Vice President, Corporate Development, and the expansion of its leadership team. “Kinnate is entering a new phase of growth as we prepare to initiate a first-in-human trial of our
15-12G - Kinnate Biopharma Inc. (0001797768) (Filer)
S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
POSASR - Kinnate Biopharma Inc. (0001797768) (Filer)
8-K - Kinnate Biopharma Inc. (0001797768) (Filer)
SC 14D9/A - Kinnate Biopharma Inc. (0001797768) (Subject)
25-NSE - Kinnate Biopharma Inc. (0001797768) (Subject)
SC TO-T/A - Kinnate Biopharma Inc. (0001797768) (Subject)
SC 14D9/A - Kinnate Biopharma Inc. (0001797768) (Subject)
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate p
EMERYVILLE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (("Kinnate", NASDAQ:KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share (together with the base price, the Cash Amount), plus one non-tradeable contingent value right ("CVR") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds from any
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors. CASTRES, France and SAN FRANCISCO, March 1, 2024 /CNW/ -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fabre Méd
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors. CASTRES, France and SAN FRANCISCO, March 1, 2024 /PRNewswire/ -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fa
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors. SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology co
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby XOMA Corporation ("XOMA") will acquire Kinnate for a price per share of Kinnate common stock ("Kinnate common stock") of between $2.3352 and $2.5879 in cash, consisting of (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of up to $0.2527 per share, plus one non-transferable contingent value right per share, representing the right to receive (a) 100% of the net proceeds payable from any dispos
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ:KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with the Base Price, the Cash Amount) at the closing of the merger plus a non-transferable contingent value right (CVR), representing the right to receive 85% of the net proceeds from any out license or sale of the Kinnate programs effected within one year of closing of the merger or 100% of the net proceeds from any out license or sale executed prior to the closing. "This
Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023Previously announced strategic reprioritization with a focus on exarafenib combination in NRAS mutant melanoma, c-MET inhibitor KIN-8741 and brain penetrant CDK4 selective program and a workforce restructuringCash, cash equivalents and investments of $180.3 million as of September 30, 2023 SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kinnate Biop
Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 selective program in the fourth quarter of 2023 Completed exarafenib monotherapy dose expansion enrollment and cleared efficacious dose for KIN-3248, FGFR inhibitor; exploring strategic alternatives for both programs Paused KIN-7136 MEK inhibitor development and implementing a workforce restructuring, aligned with reprioritization plan Cash, cash equivalents and investments of $204.3 million as of June 30, 2023, anticipate
Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023Cash, cash equivalents and investments of $204.3 million as of June 30, 2023 anticipated to fund operations into early 2025 SAN FRANCISCO and SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, today announced financial results for the second quarter of 2023 and recent corporate updates. Nima Farzan, chief executive officer of Kinnate Biopharma Inc., stated, "We are pleased to receive FDA clearance of the IND application for
Stifel downgraded Kinnate BioPharma from Buy to Hold and set a new price target of $11.00 from $35.00 previously
H.C. Wainwright initiated coverage of Kinnate BioPharma with a rating of Buy and set a new price target of $33.00
Jefferies initiated coverage of Kinnate Biopharma with a rating of Buy and set a new price target of $46.00
Stifel initiated coverage of Kinnate Biopharma with a rating of Buy and set a new price target of $32.00
William Blair initiated coverage of Kinnate BioPharma with a rating of Outperform
Piper Sandler initiated coverage of Kinnate Biopharma with a rating of Overweight and set a new price target of $52.00
As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered into a merger agreement to acquire Kinnate Biopharma Inc. (("Kinnate", NASDAQ:KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share (together with the base price, the Cash Amount), plus one non-tradeable contingent value right ("CVR") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds from any out license or sale executed prior to the closing. On M
Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors. SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology compa
Friday, XOMA Corporation (NASDAQ:XOMA) agreed to acquire Kinnate Biopharma Inc (NASDAQ:KNTE) for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share plus a non-transferable contingent value right (CVR). Kinnate Biopharma is a clinical-stage precision oncology company focused on developing cancer-targeted therapies. XOMA will commence a tender offer by March 4, 2024. In November 2023, Kinnate Biopharma’s board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company. “This acquisition will further add to our sizable cas
Wedbush analyst David Nierengarten reiterates Kinnate Biopharma (NASDAQ:KNTE) with a Neutral and maintains $2 price target.
Shares of Shapeways Holdings, Inc. (NASDAQ:SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company’s quarterly sales came in at $8.37 million versus estimates of $8.75 million. Shapeways shares fell 20.8% to $2.36 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares climbed 62.4% to $2.16 after the company reported third-quarter results. Chemomab Therapeutics Ltd. (NASDAQ:CMMB) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for
Gainers Heron Therapeutics (NASDAQ:HRTX) stock moved upwards by 63.0% to $0.88 during Wednesday's regular session. As of 12:31 EST, Heron Therapeutics's stock is trading at a volume of 15.8 million, which is 750.5% of its average full-day volume over the last 100 days. The company's market cap stands at $123.8 million. The company's, Q3 earnings came out yesterday. Kinnate Biopharma (NASDAQ:KNTE) shares increased by 57.32% to $2.47. The current volume of 55.3 million shares is 35889.2% of Kinnate Biopharma's average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $116.3 million. As per the press release, Q3 earnings cam
Kinnate Biopharma Inc's (NASDAQ:KNTE) board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company. In its SEC filing, the company said the board would consider any proposal that Foresite and OrbiMed present per the board's fiduciary duties, and with the same care and attention, it would consider other similar proposals if received by the company. In September, Kinnate Biopharma prioritized the exarafenib combination, KIN-8741, and discovery efforts around its CDK4 selective program. Kinnate also implemented a corporate restructuring by reducing the company's workforce by ap